An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          About NIAMS
          Massimo Gadina, Ph.D.





Massimo Gadina, Ph.D.


Associate Scientist
    Director, Office of Science and Technology
    Chief, Translational Immunology Section Image
              headshot of a man with short hair, wearing glasses 
            Contact Information

                                                  301-443-5457
                
                                                9000 Rockville Pike
                  
            10 Center Drive
      
                  
            Building 10, Room 10C101B
      
                                   Bethesda MD 20892
                
                                                Massimo.gadina@nih.gov 
                                          Media Resources
                                High Resolution Image
                headshot-massimo-gadina_0.jpg 
                Summary
          Dr. Massimo Gadina is the Director of the Office of Science and Technology (OST) at the NIAMS, supporting intramural researchers with core technologies. He also serves as Chief of the Translational Immunology Section of the OST. Prior to this appointment, he was Senior Lecturer at the Division of Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, The Queen's University of Belfast, Northern Ireland.
        
                  Research Statement
          
            Dr. Gadina's research interests are focused on immune-mediated diseases and specifically, the biology of cytokines and their relative signaling pathways. His translational work is also focused on autoinflammatory diseases and other inflammatory diseases. 

            Scientific Publications
              Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.

    Garufi C, Maclean M, Gadina M, Spinelli FR
        

                    Expert Rev Clin Immunol.
        
                    2022 Mar;
        
                    18(3).
        
                    doi: 10.1080/1744666X.2022.2042254
                            PMID: 35168456
  A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?

    Liu C, Kieltyka J, Fleischmann R, Gadina M, O'Shea JJ
        

                    Arthritis Rheumatol.
        
                    2021 Dec;
        
                    73(12).
        
                    doi: 10.1002/art.41906
                            PMID: 34180156
  JAK inhibitors: Ten years after.

    Spinelli FR, Meylan F, O'Shea JJ, Gadina M
        

                    Eur J Immunol.
        
                    2021 Jul;
        
                    51(7).
        
                    doi: 10.1002/eji.202048922
                            PMID: 33930196
  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

    Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell'Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC
        

                    N Engl J Med.
        
                    2020 Dec 31;
        
                    383(27).
        
                    doi: 10.1056/NEJMoa2026834
                            PMID: 33108101
  Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

    Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
        

                    Ann Rheum Dis.
        
                    2021 Mar;
        
                    80(3).
        
                    doi: 10.1136/annrheumdis-2020-218690
                            PMID: 32843325
  HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.

    Spinelli FR, Conti F, Gadina M
        

                    Sci Immunol.
        
                    2020 May 8;
        
                    5(47).
        
                    pii: eabc5367. doi: 10.1126/sciimmunol.abc5367
                            PMID: 32385052
  Translating JAKs to Jakinibs.

    Gadina M, Chisolm DA, Philips RL, McInness IB, Changelian PS, O'Shea JJ
        

                    J Immunol.
        
                    2020 Apr 15;
        
                    204(8).
        
                    doi: 10.4049/jimmunol.1901477
                            PMID: 32253269
  JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.

    Vian L, Le MT, Gazaniga N, Kieltyka J, Liu C, Pietropaolo G, Dell'Orso S, Brooks SR, Furumoto Y, Thomas CJ, O'Shea JJ, Sciumè G, Gadina M
        

                    Front Immunol.
        
                    2019;
        
                    10().
        
                    doi: 10.3389/fimmu.2019.02972
                            PMID: 31921209
  Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.

    Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D, Liu L, Stoffels M, Kratina T, Lawlor KE, Zaal KJM, Hoffmann PM, Etemadi N, Shield-Artin K, Biben C, Tsai WL, Blake MD, Kuehn HS, Yang D, Anderton H, Silke N, Wachsmuth L, Zheng L, Moura NS, Beck DB, Gutierrez-Cruz G, Ombrello AK, Pinto-Patarroyo GP, Kueh AJ, Herold MJ, Hall C, Wang H, Chae JJ, Dmitrieva NI, McKenzie M, Light A, Barham BK, Jones A, Romeo TM, Zhou Q, Aksentijevich I, Mullikin JC, Gross AJ, Shum AK, Hawkins ED, Masters SL, Lenardo MJ, Boehm M, Rosenzweig SD, Pasparakis M, Voss AK, Gadina M, Kastner DL, Silke J
        

                    Nature.
        
                    2020 Jan;
        
                    577(7788).
        
                    doi: 10.1038/s41586-019-1828-5
                            PMID: 31827281
  High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis.

    Tsai WL, Vian L, Giudice V, Kieltyka J, Liu C, Fonseca V, Gazaniga N, Gao S, Kajigaya S, Young NS, Biancotto A, Gadina M
        

                    J Immunol Methods.
        
                    2020 Feb;
        
                    477().
        
                    doi: 10.1016/j.jim.2019.112667
                            PMID: 31726053
  Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.

    Simon N, Antignani A, Hewitt SM, Gadina M, Alewine C, FitzGerald D
        

                    JCI Insight.
        
                    2019 Mar 7;
        
                    4(5).
        
                    pii: 123281. doi: 10.1172/jci.insight.123281
                            PMID: 30720466
  Selective Janus kinase inhibitors come of age.

    O'Shea JJ, Gadina M
        

                    Nat Rev Rheumatol.
        
                    2019 Feb;
        
                    15(2).
        
                    doi: 10.1038/s41584-018-0155-9
                            PMID: 30622297
  JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

    Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R
        

                    J Clin Invest.
        
                    2018 Jul 2;
        
                    128(7).
        
                    doi: 10.1172/JCI98814
                            PMID: 29649002 
          Education
              
            **Università di Milano, Italy**Doctor of Pharmaceutical Chemistry and Technology**Université de Bourgogne, Dijon, France**Diplôme de Docteur             
                        Experience
              
            **Director, Office of Science and Technology**Chief, Translational Immunology SectionNIAMS, NIH, 2009 - present**Staff Scientist, Acting Director, Office of Science and Technology**Acting Chief Translational Immunology SectionNIAMS, NIH, 2008 - 2009**Senior Lecturer, Tenured**Division of Infection and Immunity, School of Medicine Dentistry and Biomedical Sciences, The Queen’s University of Belfast, Northern Ireland, U.K., 2003 - 2008**Staff Scientist**Lymphocyte Cell Biology Section, Arthritis and Rheumatism Branch, NIAMS, NIH, 2000 - 2002**Visiting Associate**Lymphocyte Cell Biology Section, Arthritis and Rheumatism Branch, NIAMS, NIH, 1996 - 1999**Research Associate-Staff Scientist**Division of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori,Milano, Italy, 1990 - 1996.


Last Updated: November 2023


Back to Top
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy